Introduction
Ganirelix Acetate is a synthetic, high-affinity gonadotropin-releasing hormone (GnRH) antagonist developed for clinical reproductive medicine. Unlike GnRH agonists that require a "downregulation" phase to suppress hormone secretion, ganirelix acetate acts rapidly by competitively binding to GnRH receptors on pituitary gonadotroph cells, directly inhibiting the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) within hours. Its core advantage lies in preventing premature LH surges without disrupting early follicular development, making it a cornerstone drug in controlled ovarian stimulation (COS) protocols for assisted reproductive technology (ART). Below is a detailed breakdown of its applications, mechanisms, and key considerations:
1. Core Clinical Application: Assisted Reproductive Technology (ART)
The primary and most widely established use of ganirelix acetate is in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) procedures, where it optimizes follicle maturation and egg retrieval outcomes.
1.1 Preventing Premature Ovulation in Controlled Ovarian Stimulation
In COS protocols, patients receive exogenous FSH to stimulate the simultaneous development of multiple ovarian follicles. A spontaneous, premature LH surge can trigger early ovulation before follicles reach optimal maturity, leading to reduced egg retrieval rates, poor egg quality, and failed fertilization. Ganirelix acetate addresses this critical issue through targeted inhibition:
Administration timing: It is typically initiated on the 5th or 6th day of FSH stimulation (when follicles reach 10–12 mm in diameter) and continued daily until the day of human chorionic gonadotropin (hCG) administration (the trigger for final follicle maturation).
Mechanism advantage: Unlike GnRH agonists (e.g., leuprolide acetate) that initially stimulate LH release before suppressing it, ganirelix acetate exerts an immediate, dose-dependent inhibition of LH secretion. This avoids the "flare effect" of agonists, reduces the risk of ovarian hyperstimulation syndrome (OHSS), and shortens the overall duration of the stimulation protocol.
Clinical outcomes: By maintaining stable LH levels within the optimal range, ganirelix acetate increases the number of mature, retrievable oocytes, improves fertilization and embryo implantation rates, and enhances the likelihood of clinical pregnancy in ART cycles.
1.2 Flexible and Fixed COS Protocols
Ganirelix acetate is compatible with both flexible and fixed COS protocols, adapting to individual patient needs:
Fixed protocol: Administered starting on a predefined day of FSH stimulation (e.g., day 6), suitable for patients with predictable follicular development.
Flexible protocol: Initiated based on real-time follicular monitoring (e.g., when the leading follicle reaches 14 mm), ideal for patients with polycystic ovary syndrome (PCOS) or irregular follicular growth, as it allows personalized adjustment of treatment timing.
2. Other Potential Clinical Applications
While ART remains its main indication, ganirelix acetate has been investigated for off-label uses in reproductive and endocrine disorders, supported by its ability to regulate gonadotropin secretion:
2.1 Management of Endometriosis-Associated Symptoms
Endometriosis is driven by estrogen-dependent growth of endometrial tissue outside the uterus, causing chronic pelvic pain and infertility. Ganirelix acetate’s suppression of LH and FSH reduces ovarian estrogen production, which can shrink endometriotic lesions and alleviate pain symptoms. It is sometimes used as an alternative to GnRH agonists for short-term treatment, particularly in patients who cannot tolerate the bone density loss associated with long-term agonist use.
2.2 Treatment of Central Precocious Puberty (CPP)
CPP is characterized by early onset of puberty (before age 8 in girls and 9 in boys) due to premature activation of the hypothalamic-pituitary-gonadal (HPG) axis. Ganirelix acetate can suppress the excessive LH and FSH secretion that drives early sexual maturation, slowing the progression of secondary sexual characteristics and preserving adult height potential. It offers a shorter onset of action compared to agonists, making it a potential option for patients requiring rapid control of pubertal development.
2.3 Ovarian Hyperstimulation Syndrome (OHSS) Prophylaxis
OHSS is a serious complication of COS, characterized by ovarian enlargement, fluid accumulation in the abdomen and chest, and electrolyte imbalances. By avoiding the LH flare effect associated with GnRH agonists and enabling more precise control of follicular development, ganirelix acetate reduces the risk of severe OHSS, especially in high-risk patients (e.g., those with PCOS, high baseline antral follicle count).
3. Special Population Considerations
3.1 Reproductive-Age Women (Primary Target Population)
Ganirelix acetate is exclusively indicated for premenopausal women undergoing ART. Dosing is adjusted based on body weight and follicular response to stimulation, with no need for dose reduction in patients with normal liver or kidney function.
3.2 Patients with Hepatic or Renal Impairment
Limited clinical data suggest that mild to moderate hepatic or renal impairment does not significantly affect the pharmacokinetics of ganirelix acetate. However, dose adjustment may be required for patients with severe impairment, and close monitoring of hormone levels is recommended.
3.3 Contraindicated Populations
Pregnant or lactating women: Ganirelix acetate is contraindicated during pregnancy, as it may disrupt fetal development by suppressing maternal gonadotropin levels. It should also not be used during breastfeeding, as its excretion in breast milk has not been fully evaluated.
Patients with hypersensitivity: Individuals with a known allergy to ganirelix acetate or any excipients in the formulation (e.g., mannitol, acetic acid) should not receive the drug.
4. Important Notes on Application
Administration route: Ganirelix acetate is administered via subcutaneous injection in the abdominal area, thigh, or upper arm. The injection site should be rotated to avoid local irritation, and the drug should be stored refrigerated (2–8°C) before use.
Adverse reactions: The most common side effects are mild and transient, including injection site reactions (pain, redness, swelling), headache, nausea, and fatigue. Rare but serious adverse events include OHSS, hypersensitivity reactions (rash, urticaria, anaphylaxis), and ovarian torsion (associated with enlarged ovaries during stimulation).
Drug interactions: No significant drug interactions have been reported with ganirelix acetate. However, concurrent use of other gonadotropin-modulating drugs (e.g., GnRH agonists, oral contraceptives) may alter hormone levels and should be avoided unless directed by a physician.
Monitoring requirements: During treatment, patients require regular transvaginal ultrasound monitoring of follicular growth and serum LH/FSH/estradiol level testing to adjust the timing of hCG administration and ensure treatment safety.
FAQ
Q1. Can I get a free sample?
We can send you a samll free sample, and you only need to pay for the shipping cost.
Q2. What is the HyperChem payment term?
T/T in advance
LC at sight
DP at sight
Bank transfer
PayPal
Bitcoin...
Q3. What is HyperChem shipment policy?
Our policy is to strive for the quickest shipment time possible.
For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.
Q4. What is HyperChem shipment term?
By Express
FedEx UPS DHL EMS
Fast: 3-7 days around, high cost, door to door service
By Air
Suitable for more than 50kg
Fast: 3-7 days, hight cost, port to port, professional broker needed
By Sea
Suitable for more than 500kg
Fast: 7-45 days, low cost, port to port, professional broker needed
We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.
Q5. What HyperChem will provide after shipment?
For sample orders:
After shipment is done, an timely email including:
1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice
For commercial orders:
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.
Egypt
